Clinical Trial

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-24.
Trial Details
NCT Number NCT06755684
Lead Sponsor Peng Zhang
Conditions EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed, Carboplatin, Bevacizumab, Antineoplastic Agents, Tyrosine Kinase Inhibitor
Enrollment 60 participants
Start Date 2024-11-07
Primary Completion 2025-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-06